Chronic in vivo treatment with either BAY 58-2667 or BAY 41-2272, using relatively high doses of sGC ligand, has been shown previously to limit left ventricular hypertrophy in a range of hypertension-driven experimental models [16]–[20]. The gene discussed is SGCB; the disease is left ventricular hypertrophy.